INS and Insulin resistance: We also reported improvements in measures of glucose metabolism and insulin resistance (ie, HbA1C, insulin, and homeostatic model of insulin resistance) and decreases in very-low-density lipoprotein cholesterol and triglycerides and an increase in high-density lipoprotein cholesterol in participants receiving semaglutide [19].